Pfizer Inc. failed to convince advisers to the US Food and Drug Administration to support a dramatic expansion in the use of its prostate cancer drug, a setback that could scuttle the company’s ...

(Bloomberg) -- Pfizer Inc. failed to convince advisers to the US Food and Drug Administration to support a dramatic expansion in the use of its prostate cancer drug, a setback that could scuttle ...

A dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. (NYSE ... clinical data for Padcev in urothelial cancer. Talzenna also showed positive overall survival data in ...

In its latest setback, Merck has announced ... in combination with Astellas/Pfizer’s Xtandi (enzalutamide) in metastatic castration-resistant prostate cancer (mCRPC) – its last remaining ...

A dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc ... in urothelial cancer. Talzenna also showed positive overall survival data in prostate cancer, though ...

A US district court has said that a key patent held by Astellas on its Myrbetriq drug for urinary incontinence is invalid, in a setback ... for Pfizer-partnered prostate cancer therapy Xtandi ...

Talzenna is currently approved in combination with Xtandi (enzalutamide) for individuals with castration-resistant prostate cancer that have the HRR gene mutation. Pfizer submitted an sNDA to have the ...

In a somber end to an FDA advisory committee’s two-day scouring of multiple drugmakers’ oncology data, Pfizer’s pitch to ...

A U.S. FDA panel of independent experts beat back an effort by Pfizer (NYSE:PFE) to expand the patient population for its prostate cancer treatment Talzenna (talazoparib). Members of the Oncologic ...

Astellas Pharma (ALPMY) and Pfizer (PFE) announced longer-term follow-up results from an open-label extension of the Phase 3 ...